Emergence of bedaquiline-resistance in a high-burden country of tuberculosis.
Elena ChesovDumitru ChesovFlorian P MaurerSönke AndresChristian UtpatelIvan BarilarAna DonicaMaja ReimannStefan NiemannChristoph LangeValeriu CruduJan HeyckendorfMatthias MerkerPublished in: The European respiratory journal (2021)
MDR-TB treatments based on bedaquiline require a functional background regimen to achieve high cure rates and to prevent the evolution of bedaquiline resistance. Novel MDR-TB therapies with bedaquiline require timely and comprehensive drug resistance monitoring.